Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients

Journal of Clinical Oncology

Volumn 22, Issue 22, 2004, Pages 4463-4473

  King, David M ^a   Albertini, Mark R ^a   Schalch, Heidi ^a   Hank, Jacquelyn A ^a   Gan, Jacek ^a   Surfus, Jean ^a   Mahvi, David ^a   Schiller, Joan H ^a   Warner, Thomas ^a   Kim, KyungMann ^a   Eickhoff, Jens ^a   Kendra, Kari ^a   Reisfeld, Ralph ^a   Gillies, Stephen D ^a   Sondel, Paul ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EMD 273063; OPIATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EMD 273063 ANTIBODY, HUMAN;

ARTHRALGIA; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; IN VIVO STUDY; LIVER DISEASE; LYMPHOCYTOSIS; MELANOMA; MYALGIA; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADULT; AGED; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SKIN TUMOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 16544364126     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.035     Document Type: Article

References (32)

1. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature, 411: 380-384, 2001
2. Mule JJ, Yang JC, Lafeniere R, et al: Identification of cellular mechanisms operation in vivo during the regression of established pulmonary metastases by the systemic administration of high dose recombinant interleukin-2. J Immunol 139:285-295, 1987
3. Albertini MR, Sondel PM: Tumor immunology and immunotherapy, in Abeloff MD, Armitage JO, Lichter AS, et al (eds): Clinical Oncology (ed 2). Philadelphia, PA, Churchill Livingstone, 2000, pp 214-241
4. Colucci F, Caligiuri MA, Di Santo JP: What does it take to make a natural killer? Nat Rev Immunol 3:413-425, 2003
5. Harel W, Shau H, Hadley CG, et al: Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Cancer Res 50:6311-6315, 1990
6. Hank JA, Robinson RR, Surfus J, et al: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res 50:5234-5239, 1990
7. Shiloni E, Euisenthal A, Sachs D, et al: Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin-2. J Immunol 138:1992-1998, 1987
8. Bernstein N, Stames C, Levy R: Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2. J Immunol 140:2839-2845, 1988
9. Schultz KR, Peace DJ, Badger CC, et al: Monoclonal antibody therapy of murine lymphoma: Enhanced efficacy by concurrent administration of interleukin-2 or lymphokine-activated-killer cells. Cancer Res 50:5421-5425, 1990
10. Becker JC, Pancook JD, Gillies SD, et al: T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 183:2361, 1996
11. Lode HN, Xiang R, Dreier T, et al: Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:1706, 1998
12. Mujoo K, Cheresh D, Yang HM, et al: Disialoganglioside GD2 on human neuroblastoma: Target antigen for monoclonal antibody mediated cytolysis and suppression of tumor growth. Cancer Res 47:1098-1104, 1987
13. Cheung NK, Saarinen UM, Neely JE, et al: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45: 2642-2649, 1985
14. Hank JA, Surfus JE, Can J, et al: Activation of human effector cells by a tumor reactive recombinant anti-ganglioside- GD2/interleukin-2 immunocytokine (ch14.18-IL-2). Clin Cancer Res 2:1951-1959, 1996
15. Storer B: Design and analysis of phase I clinical trials. Biometrics 45:925-937, 1989
16. Albertini MR, Hank JA, Schiller JH, et al: Phase IB trial of chimeric anti-GD2 antibody plus interleukin-2 for melanoma patients. Clin Cancer Res 3:1277-1288, 1997
17. Hank JA, Weil-Hillman G, Surfus JE, et al: Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunol Immunother 31: 53-59, 1990
18. Farner NL, Can J, de Jong JLO, et al: Alteration of the CD34+ Tf-1beta cell line profile in response to long-term exposure to IL-15. Cytokine 9:316-327, 1997
19. Can J, Kendra K, Ricci M, et al: Specific ELISA systems for quantitation of antibody-cytokine fusion proteins. Clin Diagn Lab Immunol 6:236-242, 1999
20. Hank JA, Surfus JE, Can J, et al: Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody: Interleukin-2 immunocytokine, in Buolamwini JK, Adjei AA (eds): Methods in Molecular Medicine (vol 85). Totowa, NJ, Humana Press, 2003. pp 123-131
21. Lindsey JK: Models for Repeated Measurements. Oxford. United Kingdom, Oxford University Press, 1993
22. Kendra K, Gan J, Ricci M, et al: Pharmacokinetics and stability of the 14.18-IL-2 fusion protein in mice. Cancer Immunol Immunother 48:219-229, 1999
23. Scott AM, Lee F-T, Hopkins W, et al: Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: Results of a phase I trial. J Clin Oncol 19:3976-3987, 2001
24. Sondel PM, Hank JA, Gan J, et al: Preclinical and clinical development of immunocytckines. Curr Opin Investig Drugs 4:695-700, 2003
25. Becker JC, Pancook JD, Gillies SD, et al: Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin-2 fusion proteins. Proc Natl Acad Sci U S A 93:2702-2707, 1996
26. Lode HN, Xiang R, Varki NM, et al: Targeted interleukin-2 therapy of spontaneous neuroblastoma to bone marrow. J Natl Cancer Inst 89:1586-1591, 1997
27. Frost JD, Ettinger LJ, Hank JA, et al: Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus IL-2 in children with refractory neuroblastoma: A report of the Children's Cancer Group. Cancer 80:317-333, 1997
28. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al: Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16:2169-2180, 1998
29. Ozkaynak F, Sondel P. Krailo M, et al: A phase I study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody (ch14.18) with GM-CSF in children with neuroblastoma immediately post hematopoietic stem cell transplantation: A Children's Cancer Group Study. J Clin Oncol 18:4077-1085, 2000
30. Webb DE, Austen HA, Belldegrun A, et al: Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 30:141-145, 1988
31. Kozeny GA, Nicolas JD, Creekmore S, et al: Effects of interleukin-2 immunotherapy on renal function. J Clin Oncol 6:1170-1176, 1988
32. Soni N, Meropol NJ, Porter M, et al: Diabetes mellitus induced by low-dose interleukin-2. Cancer Immunol Immunother 43:59-62, 1996